Divi's Laboratories Limited has notified the stock exchanges of two key corporate events scheduled for May 23, 2026 — a Board of Directors meeting to approve audited financial results for the quarter and year ended March 31, 2026, and an earnings conference call for investors and analysts. The filings have been made in compliance with Regulation 29 and Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, respectively.

Board Meeting: Key Agenda Items

The Board meeting has been convened to deliberate on the following matters:

• Approval of audited standalone and consolidated financial results for the quarter and year ended March 31, 2026
• Recommendation of dividend, if any, on equity shares of the Company for the financial year 2025-26

The following table summarises the key details of the scheduled Board meeting:

Earnings Conference Call Details

Following the release of audited financial results, the management of Divi's Laboratories will host an earnings conference call on May 23, 2026, at 14:30 hrs (IST) to discuss the Company's financial performance. A transcript of the conference call will be made available on the Company's website at www.divislabs.com . The schedule was filed pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, on May 15, 2026.

Participants may join the call through either of the following options:

Participants joining via dial-in are advised to connect approximately five minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call.

Trading Window Closure

In line with the company's earlier intimation dated March 31, 2026, the Trading Window for dealing in the securities of Divi's Laboratories has been closed since April 01, 2026. The Trading Window will remain closed until May 25, 2026, which is 48 hours after the scheduled declaration of financial results. This closure applies to all designated persons and is in compliance with applicable SEBI regulations.

Both intimations were signed by M. Satish Choudhury, Company Secretary & Compliance Officer, on behalf of Divi's Laboratories Limited.

Divi's Laboratories Limited has submitted its quarterly compliance certificate to stock exchanges for the quarter ended March 31, 2026, in accordance with SEBI regulatory requirements. The pharmaceutical company filed the mandatory certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Submission

The compliance certificate was submitted to both major Indian stock exchanges where the company's shares are listed. Company Secretary & Compliance Officer M. Satish Choudhury signed and submitted the documentation on April 06, 2026.

Certificate Confirmation Details

KFin Technologies Limited, serving as the Registrar & Share Transfer Agent, provided confirmation regarding the dematerialization process for the quarter. Deputy Vice President Ganesh Chandra Patro signed the certificate on April 02, 2026, confirming compliance with regulatory requirements.

The certificate confirms several key operational aspects:

• Securities received from depository participants for dematerialization were properly confirmed to depositories
• All securities have been listed on BSE Limited and National Stock Exchange of India Limited
• Security certificates received for dematerialization were mutilated and cancelled after verification
• Depository names were substituted in the register of members within the mandated 15-day period

Stock Exchange Communication

The submission was made to both primary stock exchanges where Divi's Laboratories shares are traded. The company maintains its listing on National Stock Exchange of India Limited and BSE Limited, ensuring compliance across all trading platforms.

This quarterly submission represents standard regulatory compliance for listed companies, ensuring transparency in securities handling and depository operations. The certificate validates that all dematerialization processes during the quarter were conducted in accordance with SEBI guidelines and exchange requirements.